MVA-BN as monkeypox vaccine for healthy and immunocompromised
E.T. Overton, S. Lawrence, J. Stapleton and 9 more
International Journal of Infectious Diseases · 2020
doi:10.1016/j.ijid.2020.09.1217 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Background: Over 100 monkeypox (MPX) cases were reported in Nigeria since 2017, with travelers to the UK, Israel, and Singapore becoming ill and incidents of secondary transmission further raising concerns. MVA-BN (JYNNEOS) is the only approved MPX vaccine, with nonclinical and clinical evidence supporting its safety and efficacy.
Abstract licence: CC BY-NC-ND
Cited by papers we hold1
Monkeypox: A New Threat? · 2022
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.